2 HOLTZMAN ST., SCIENCE PARK, REHOVOT, L3
Announces Expansion of Biosimilars Portfolio with the Launch of Two Additional Products in Israel
Files Form 6-K with SEC Regarding Administrative Error
CDC Highlights Significant Increase in U.S. Rabies Exposures and Anti-Rabies Immunoglobulin Utilization
To Present at the H.C. Wainwright 28th Annual Global Investment Conference
Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholders
Declares Cash Dividend of $0.17 Per Share
Kamada Reports Record-High 2026 Financial Results and Growth
Holds Annual General Meeting of Shareholders
Annual and Transition Report of Foreign Private Issuers
Amended Annual and Transition Report of Foreign Private Issuers
Effectiveness Notice
Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
No filings found
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload
Confidential Treatment Order